Table 1.

Fas-FasL and TNF are not required for the inhibition of TCR-stimulated bystander CD8 T cell proliferation^a

No. of expts	Source of TCR transgene	Host mice	Treatment	Functional		Avg fold inhibition ± SD
				Fas-FasL	TNF/TNFR
7	HY	WT		+	+	4.2 ± 1.4
8	P14	WT		+	+	4.4 ± 1.9
2	HY	gld		−	+	4.9 ± 1.9
4	HY/lpr	WT		−	+	4.4 ± 1.1
4	P14	gld		−	+	4.5 ± 3.7
3	HY	WT	Etanercept	+	−	4.0 ± 1.6
3	P14	WT	Etanercept	+	−	5.1 ± 4.5
1	HY	gld	Etanercept	−	−	4.3 ± 0.0
1	HY/lpr	WT	Etanercept	−	−	4.1 ± 0.0
2	P14	gld	Etanercept	−	−	3.8 ± 0.9

^aHY or HY/lpr-transgenic CD8 T cells were adoptively transferred into naïve or day 5 LCMV-infected WT or gld recipient male mice. Two days after adoptive transfer, the numbers of HY CD8 T cells in the spleens of individual mice were determined. P14 transgenic CD8 T cells were adoptively transferred into naïve WT or gld recipient mice, followed by infection with 1.5 × 10⁷ PFU PV i.p. At day 5 of PV infection, mice were inoculated with GP_33-45 i.v. Two days after peptide treatment, the numbers of P14 CD8 T cells in the spleens of individual mice were determined. Etanercept-treated mice were inoculated with 100 μg etanercept i.p. at day 4 of virus infection (1 day prior to transgenic T cell activation). Fold inhibition was calculated as the number of transgenic CD8 T cells in naïve mice over the number of transgenic CD8 T cells in virus-infected mice. The numbers of independent experiments are indicated, and the average levels of inhibition (n-fold) for all experiments performed ± standard deviations are shown.